

NEW!

Flavalta™

LIDOCAINE HYDROCHLORIDE 2%
AND EPINEPHRINE 1:100,000

THE FIRST AND ONLY LIDOCAINE
WITH FLAVORING AGENTS




Lidocaine

First synthesized in 1943 and marketed in 1948, Lidocaine was the first amino-amide local anesthetic to be sold in dental cartridges.¹ Lidocaine represented a major pharmaceutical breakthrough by offering a lower risk of allergic reactions compared to ester-based anesthetics. Over the years Lidocaine has achieved the “gold standard” status for dental anesthetics and is commonly used to provide reliable local anesthesia in everyday dentistry.

Bitter Aftertaste

It is well documented that dental injectable formulations of Lidocaine hydrochloride can result in a bitter aftertaste for the patient.²⁻⁵ In a recent survey, 99% of dental professionals (n=150) were aware that injectable formulations of Lidocaine can be unpleasant to taste, noting that 99% of their patients describe the taste as “bitter.” In the same survey, dental professionals noted 93% of patients described tasting Lidocaine as a negative experience.⁶

Flavalta™




Flavalta™ is the first and only Lidocaine with flavoring agents. Flavalta™ contains sodium saccharin, a non-nutritive artificial sweetener, and L-Serine, a non-essential amino acid used to offset bitterness. Both Saccharin and L-Serine have been approved by the FDA for safe use as sweetening and flavor enhancing agents and can be used in food, beverages, and drugs.⁷

Flavalta™

Lidocaine Hydrochloride 2% and Epinephrine 1:100,000
*99379: 50 Cartridges/Box

1. Malamed, S. F. (2020). Clinical Action of Specific Agents. Handbook of Local Anesthesia (pp. 64–64). essay, Elsevier.
2. Wei Y, Nedley MP, Bhaduri SB, Bredzinski X, Boddur SH. Masking the bitter taste of injectable lidocaine HCl formulation for dental procedures. AAPS PharmSciTech. 2015 Apr;16(2):455-65. doi: 10.1208/s12249-014-0239-z. Epub 2014 Nov 1. PMID: 25361901; PMCID: PMC4370974.
3. Boddur SHS, Tukaramrao DB, Al-Tabakha MM, Ashames A, Neupane R, Babu RJ, Renukuntla J, Tiwari AK. Evaluation of Cytotoxicity and Taste-Masking Effect of Selected Flavors on Dental Lidocaine HCl Injection. Pharmaceuticals (Basel). 2020 Oct 29;13(11):353. doi: 10.3390/ph13110353. PMID: 33138130; PMCID: PMC7693877.
4. Uzbilger Feldman D, Laun BB II, Patel C, Pande SV, Boddur SHS. A Buffered Local Anesthetic Without Epinephrine: Development, Characterization, and In Vivo Efficacy and Toxicity Analysis. Pharmaceuticals. 2024; 16(8):1058. <https://doi.org/10.3390/pharmaceutics16081058>
5. HARBERT H. Counteracting the bitter taste of local anesthetic. The Journal of the American Dental Association, 132, 1418-1419
6. Key Group Consultative Market Research - Dental Anesthetic Assessment Survey - July 2023
7. Center for Food Safety and Applied Nutrition. Aspartame and other sweeteners in food. U.S. Food and Drug Administration. <https://www.fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food>

Lidocaine



Upon its introduction, Lidocaine hydrochloride replaced Procaine (Novocain) for both medical and dental uses.¹ In comparison, Lidocaine has a more rapid onset of action, produces more profound anesthesia, and has a longer duration of action.


When used for infiltration anesthesia in dental patients, 2% Lidocaine with epinephrine 1:100,000 can result in:

- An average onset time of less than 2 minutes
- An average pulp anesthesia of at least 60 minutes
- An average duration of soft tissue anesthesia of approximately 2½ hours

When used for nerve-block anesthesia in dental patients, 2% Lidocaine with epinephrine 1:100,000 can result in:

- An average onset time between 2 – 4 minutes
- An average pulp anesthesia of at least 90 minutes
- An average duration of soft tissue anesthesia between 3 – 3 ½ hours


Saccharin



Saccharin brand names include Sweet and Low®, Sweet Twin®, Sweet’N Low®, and Necta Sweet®. It is 200 to 700 times sweeter than table sugar (sucrose) and contains no calories.¹

The FDA has regulated saccharin as a food additive since 1977. First discovered and used in 1879, saccharin is currently approved for use, under certain conditions, in beverages, fruit juice drinks, and bases or mixes when prepared for consumption per directions, as a sugar substitute for cooking or table use, and in processed foods. Saccharin is also listed for use for certain technological purposes.²

L-Serine



L-Serine is a non-essential amino acid that is Generally Recognized as Safe (GRAS) by the FDA for use as a nutrient, flavor enhancer, or flavoring agent in food and drugs.³ L-serine has a well-established safety profile and broad relevance to human physiology and cellular integrity.⁴

1-2. Center for Food Safety and Applied Nutrition. Aspartame and other sweeteners in food. U.S. Food and Drug Administration. <https://www.fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food>

3. U.S. Food and Drug Administration (FDA). Substances Added to Food: L-Serine (CAS No. 56-45-1). <https://hfpaexternal.fda.gov/scripts/oc/index.cfm?set=FoodSubstances&id=SERINE>

4. Holm LJ, Buschard K. L-serine: a neglected amino acid with a potential therapeutic role in diabetes. *APMIS*. 2019 Oct;127(10):655-659. doi: 10.1111/apm.12987. Epub 2019 Sep 2. PMID: 31344283; PMCID: PMC6851881.

Survey Results

In July, 2023, 150 Dentists were surveyed to assess patient and Dentist awareness of local anesthetic taste profiles and understand the extent to which taste impacts patient care.

Within this survey, the majority of Dentists responded that they use Lidocaine as their primary anesthetic formulation – noting its reliability, effectiveness, and cost as top reasons for why they prefer Lidocaine over other available formulations.

99% of dentists

are aware that Lidocaine is unpleasant to taste

91% of dentists

have had patients comment on the taste of Lidocaine

99% of patients

who commented on the taste of Lidocaine describe the taste as “Bitter”

93% of patients

who commented on the taste of Lidocaine noted that it was a negative experience

Dentists commented that patients are most likely to accidentally taste lidocaine before, during, and after intraligamentary and palatal injections

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use FLAVALTA safely and effectively.

See full prescribing information for FLAVALTA.

FLAVALTA (lidocaine hydrochloride and epinephrine injection) for infiltration or perineural block.

Initial U.S. Approval: 1985

INDICATIONS AND USAGE

FLAVALTA solution is a combination of lidocaine, an amide local anesthetic, and epinephrine, an alpha and beta adrenergic agonist indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques.

DOSAGE AND ADMINISTRATION

- See Full Prescribing Information for recommended dosages and administration information for adult and pediatric patients.

DOSAGE FORMS AND STRENGTHS

Injection: lidocaine hydrochloride 2% (34 mg/1.7 mL) (20 mg/mL) and epinephrine 1:100,000 (0.017 mg/1.7 mL) (0.01 mg/mL) as a clear, colorless solution in single-dose glass cartridges (3)

CONTRAINDICATIONS

- Known history of hypersensitivity to lidocaine or to any local anesthetics of the amide-type or to other components of FLAVALTA (4)

WARNINGS AND PRECAUTIONS

- Dose-Related Toxicity:** Monitor cardiovascular and respiratory vital signs and patient's state of consciousness after injection of FLAVALTA. (5.1)
- Methemoglobinemia:** Cases of methemoglobinemia have been reported in association with local anesthetic use. See full prescribing information for more detail on managing these risks. (5.2)
- Allergic-Type Reactions to Sulfites in FLAVALTA and Anaphylactic Reactions:** FLAVALTA contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people (5.4)
- Risk of Systemic Toxicities with Unintended Intravascular Injection:** Unintended intravascular injection may be associated with systemic toxicities, including CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Aspirate for blood prior to each dose (5.9)

ADVERSE REACTIONS

Most common adverse reactions are related to the central nervous system and the cardiovascular system.

To report SUSPECTED ADVERSE REACTIONS, contact Septodont at 1-888-888-1441 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Local Anesthetics:** The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. (7.1)
- Monoamine Oxidase Inhibitors and Tricyclic Antidepressants:** Administration of FLAVALTA, which contains epinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. (5.3, 7.2)
- Ergot-Type Oxytocic Drugs:** Concurrent administration FLAVALTA, which contains epinephrine, and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (5.3, 7.3)
- Nonselective Beta-Adrenergic Antagonists:** Administration of FLAVALTA (containing a vasoconstrictor, epinephrine), in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided (5.3, 7.4).
- Drugs Associated with Methemoglobinemia:** Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (7.5)
- Potent Inhalation Anesthetics:** Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics. (5.10, 7.6)

USE IN SPECIFIC POPULATIONS

- Pediatric Use:** Dosages in pediatric population should be reduced, commensurate with body weight and physical condition. (8.4)
- Geriatric Use:** Elderly patients should be given reduced doses commensurate with their age and physical condition (8.5)
- Hepatic Impairment:** Consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with hepatic impairment (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 03/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Dosage and Administration Information
- 2.2 Recommended Concentration and Dosages of FLAVALTA

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Dose-Related Toxicity
- 5.2 Methemoglobinemia
- 5.3 Risk of Adverse Reactions Due to Drug Interactions with FLAVALTA
- 5.4 Allergic-Type Reactions to Sulfites in FLAVALTA
- 5.5 Risk of Toxicity in Patients with Hepatic Impairment
- 5.6 Risk of Use in Patients with Impaired Cardiovascular Function
- 5.7 Risk of Ischemic Injury or Necrosis in Body Areas with Limited Blood Supply
- 5.8 Risk of Adverse Reactions with Use in Head and Neck Area
- 5.9 Risk of Systemic Toxicities with Unintended Intravascular Injection
- 5.10 Risk of Cardiac Arrhythmias with Concomitant Use of Potent Inhalation Anesthetics
- 5.11 Risk of Inadvertent Trauma to Tongue, Lips, and Buccal Mucosa

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

- 7.1 Local Anesthetics
- 7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants
- 7.3 Ergot-Type Oxytocic Drugs

- 7.4 Nonselective Beta-Adrenergic Antagonists
- 7.5 Drugs Associated with Methemoglobinemia
- 7.6 Potent Inhalation Anesthetics
- 7.7 Phenothiazines and Butyrophenones

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment

10 OVERDOSAGE

- 10.1 Clinical Presentation
- 10.2 Management of local anesthetic emergencies

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

FLAVALTA solution is indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques [see *Dosage and Administration* (2.2)].

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosage and Administration Information

- Visually inspect this product for particulate matter and discoloration prior to administration. Solution that is discolored and/or contains particulate matter should not be used and any unused portion of a cartridge of FLAVALTA should be discarded.
- Local anesthetic procedures should not be performed when there is inflammation and/or sepsis in the region of the proposed injection.
- The dosage of FLAVALTA (lidocaine HCl and epinephrine) depends on the physical status of the patient, the area of the oral cavity to be anesthetized, the vascularity of the oral tissues, and the technique of anesthesia used. The least volume of solution that results in effective local anesthesia should be administered; time should be allowed between injections to observe the patient for manifestations of an adverse reaction.
- Mixing or the prior or intercurrent use of any other local anesthetic with FLAVALTA is not recommended because of insufficient data on the clinical use of such mixtures.

Administration Precautions

- FLAVALTA should be in carefully adjusted dosages by or under the supervision of experienced clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies which might arise.
- Use FLAVALTA only if the following are immediately available: oxygen, cardiopulmonary resuscitative equipment and drugs, and the personnel resources needed for proper management of toxic reactions and related emergencies [see *Warnings and Precautions* (5.1), *Adverse Reactions* (6), *Overdosage* (10)].
- The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity when additional local anesthetics are administered with FLAVALTA [see *Warnings and Precautions* (5.1), *Drug Interactions* (7.1), *Overdosage* (10)].
- Aspirate for blood prior to injecting FLAVALTA, both the initial dose and all subsequent doses, to avoid intravascular injection. However, a negative aspiration for blood does not ensure against an intravascular injection [see *Warnings and Precautions* (5.9)].
- Avoid rapid injection of a large volume of FLAVALTA and use fractional (incremental) doses when feasible.
- Perform careful and constant monitoring of cardiovascular and respiratory (adequacy of oxygenation and ventilation) vital signs and the patient's level of consciousness after each local anesthetic injection.
- Use FLAVALTA in carefully restricted quantities in areas that may have compromised blood supply [see *Warnings and Precautions* (5.7)].

2.2 Recommended Concentration and Dosages of FLAVALTA

Adult: For normal healthy adults, the amount of lidocaine HCl administered should be kept below 500 mg and should not exceed 7 mg/kg of body weight. Dosage requirements should be determined on an individual basis. In oral infiltration and/or mandibular block, initial dosages of 1 mL to 5 mL ($\frac{1}{2}$ to 2 $\frac{1}{2}$ cartridges) of FLAVALTA (lidocaine HCl 2% solution with a 1:100,000 epinephrine concentration) are usually effective.

Pediatric: For pediatric patients who have a normal lean body mass and normal body development, the dose of lidocaine HCl is determined by the child's body weight. The lowest effective dose should be used. The maximum dose of lidocaine hydrochloride should not exceed 7 mg/kg. In children under 10 years of age, it is rarely necessary to administer more than one-half cartridge (0.9 mL to 1 mL or 18 mg to 20 mg of lidocaine) per procedure to achieve local anesthesia for a procedure involving a single tooth. In maxillary infiltration, this amount will often suffice for the treatment of two or even three teeth. In the mandibular block, however, satisfactory anesthesia achieved with this amount of drug will allow treatment of the teeth of an entire quadrant. Aspiration is recommended since it reduces the possibility of intravascular injection, thereby keeping the incidence of adverse events and anesthetic failures to a minimum. Injection should always be made slowly.

3 DOSAGE FORMS AND STRENGTHS

Injection: lidocaine hydrochloride 2% (34 mg/1.7 mL) (20 mg/mL) and epinephrine 1:100,000 (0.017 mg/1.7 mL) (0.01 mg/mL) as a clear, colorless solution in single-dose glass cartridges

4 CONTRAINDICATIONS

FLAVALTA is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations.

5 WARNINGS AND PRECAUTIONS

5.1 Dose-Related Toxicity

The safety and effectiveness of FLAVALTA depends on proper dosage, correct technique, adequate precautions and readiness for emergencies. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after each local anesthetic injection.

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. Signs and symptoms of depressed cardiovascular function may commonly result from a vasovagal reaction, particularly if the patient is in an upright position: placing the patient in the recumbent position is recommended when an adverse response is noted after injection of a local anesthetic. Vasovagal reactions may elicit a range of clinical manifestations, from prodrome signs of pre-syncope (e.g. lightheadedness, pallor, nausea, sweating, visual disturbances, weakness) to brief loss of consciousness (i.e. syncope).

Delay in proper management of dose-related toxicity, underventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest, and, possibly, death. Resuscitative equipment, oxygen and other resuscitative drugs should be available for immediate use [see *Adverse Reactions* (6)]. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption. Use the lowest dosage of FLAVALTA that results in effective anesthesia to avoid high plasma levels and serious adverse effects. Avoid rapid injection of a large volume of FLAVALTA solution and administer fractional (incremental) doses when feasible. Injection of repeated doses of lidocaine may cause significant increases in blood levels with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age and physical status.

5.2 Methemoglobinemia

Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue FLAVALTA and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

5.3 Risk of Adverse Reactions Due to Drug Interactions with FLAVALTA

Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants.

Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result in severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential [see *Drug Interactions* (7.2)].

Risk of Severe, Persistent Hypertension or Cerebrovascular Accidents Due to Drug Interactions Between FLAVALTA and Ergot-Type Oxytocic Drugs.

Concurrent administration of FLAVALTA and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see *Drug Interactions* (7.3)].

Risk of Hypertension and Bradycardia Due to Drug Interactions Between FLAVALTA and Nonselective Beta-Adrenergic Antagonists.

Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see *Drug Interactions* (7.4)].

5.4 Allergic-Type Reactions to Sulfites in FLAVALTA

FLAVALTA solution contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non asthmatic people.

5.5 Risk of Toxicity in Patients with Hepatic Impairment

Because amide-type local anesthetics such as lidocaine are metabolized by the liver, consider using reduced dosing and increased monitoring in patients with moderate and severe hepatic impairment who are treated with FLAVALTA, especially with repeat doses [see *Uses in Specific Populations* (8.6)].

5.6 Risk of Use in Patients with Impaired Cardiovascular Function

FLAVALTA should also be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heart block) because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by FLAVALTA. Monitor patients closely for blood pressure, heart rate, and ECG changes.

5.7 Risk of Ischemic Injury or Necrosis in Body Areas with Limited Blood Supply

Use FLAVALTA in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply. Patients with peripheral vascular disease or hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. Ischemic injury (such as exfoliating or ulcerating lesions) or necrosis may result.

5.8 Risk of Adverse Reactions with Use in Head and Neck Area

Small doses of local anesthetics injected into the head and neck area for dental treatment may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injection of larger doses. Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Monitor circulation and respiration and constantly observe patients receiving FLAVALTA. Resuscitative equipment and drugs, and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded [see *Dosage and Administration* (2.2)].

5.9 Risk of Systemic Toxicities with Unintended Intravascular Injection

Unintended intravascular injection of FLAVALTA may be associated with systemic toxicities, including CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Aspirate for blood before all injections of FLAVALTA to avoid intravascular injection. However, a negative aspiration for blood does not ensure against an intravascular injection.

5.10 Risk of Cardiac Arrhythmias with Concomitant Use of Potent Inhalation Anesthetics

Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics [see *Drug Interactions* (7.6)]. In deciding whether to concurrently use FLAVALTA with potent inhalation anesthetics in the same patient, the combined action of both agents upon the myocardium, the concentration and volume of vasoconstrictor used, and the time since injection, when applicable, should be taken into account.

5.11 Risk of Inadvertent Trauma to Tongue, Lips, and Buccal Mucosa

Because of the long duration of anesthesia when FLAVALTA is administered, warn patients about the possibility of inadvertent trauma to tongue, lips, and buccal mucosa and advise them not to chew solid foods until sensation returns [see *Patient Counseling Information* (17)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions have been reported and described in the Warnings and Precautions section of the labeling:

- Dose-Related Toxicity [see *Warnings and Precautions* (5.1)]
- Methemoglobinemia [see *Warnings and Precautions* (5.2)]
- Severe, Persistent Hypertension, Cerebrovascular Accidents, and Bradycardia Due to Drug Interactions [see *Warnings and Precautions* (5.3)]
- Allergic-Type Reactions [see *Warnings and Precautions* (5.4)]
- Systemic Toxicities with Unintended Intravascular Injection [see *Warnings and Precautions* (5.9)]

The following adverse reactions from voluntary reports or clinical studies have been reported with lidocaine or lidocaine and epinephrine. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions to FLAVALTA are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation.

The most commonly encountered acute adverse reactions that demand immediate counter measures were related to the CNS and the cardiovascular system. These adverse reactions were generally dose-related and due to high plasma levels which may have resulted from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution.

Persistent paresthesias of the lips, tongue, and oral tissues have been reported with the use of lidocaine, with slow, incomplete, or no recovery. These adverse events have been reported primarily following nerve blocks in the mandible involving the trigeminal nerve and its branches.

Nervous System Disorders

Adverse reactions were characterized by excitation and/or depression of the central nervous system and included lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest.

The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient. Neurologic effects following administration have included persistent anesthesia, paresthesia, weakness, paralysis, all with slow, incomplete, or no recovery.

Convulsions: Incidence varied with the procedure used and the total dose administered. The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient.

Cardiac Disorders: High doses or unintentional intravascular injection have led to high plasma levels of lidocaine and related depression of the myocardium, decreased cardiac output, heart block, hypotension, bradycardia, ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation, and cardiac arrest [see *Warnings and Precautions* (5.9)]. In addition, the beta-adrenergic receptor stimulating action of epinephrine may lead to excitatory cardiovascular responses, such as tachycardia, palpitations, and hypertension.

Vasovagal Reactions: dizziness, loss of consciousness, nausea, diaphoresis, syncope, and hypotension.

Immune System Disorders

Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to sulfites in epinephrine-containing solutions. [see *Warnings and Precautions* (5.4)].

There have been no reports of cross sensitivity between lidocaine hydrochloride and procainamide or between lidocaine hydrochloride and quinidine.

Hematologic

Methemoglobinemia [see *Warnings and Precautions* (5.2)].

7 DRUG INTERACTIONS

7.1 Local Anesthetics

The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with FLAVALTA cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see *Dosage and Administration* (2.1), *Warnings and Precautions* (5.1)].

7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential [see *Warnings and Precautions* (5.3)].

7.3 Ergot-Type Oxytocic Drugs

Concurrent administration of FLAVALTA and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see *Warnings and Precautions* (5.3)].

7.4 Nonselective Beta-Adrenergic Antagonists

Administration of FLAVALTA solution (containing a vasoconstrictor, epinephrine), in patients receiving a nonselective beta-adrenergic antagonist may result in dose-dependent hypertension and bradycardia with possible heart block. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see *Warnings and Precautions* (5.3)].

7.5 Drugs Associated with Methemoglobinemia

Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics [see *Warnings and Precautions* (5.2)].

Examples of Drugs Associated with Methemoglobinemia:

Class	Examples
Nitrates/Nitrites	nitric oxide, nitroglycerin, nitroprusside, nitrous oxide
Local anesthetics	articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine
Antineoplastic agents	cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase
Antibiotics	dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides
Antimalarials	chloroquine, primaquine
Anticonvulsants	phenobarbital, phenytoin, sodium valproate
Other drugs	acetaminophen, metoclopramide, quinine, sulfasalazine

7.6 Potent Inhalation Anesthetics

Serious dose-related cardiac arrhythmias may occur if preparations containing epinephrine are used in patients during or following the administration of potent inhalation anesthetics [see *Warnings and Precautions* (5.10)].

7.7 Phenothiazines and Butyrophenones

Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of FLAVALTA and these agents should generally be avoided. In situation when concurrent therapy is necessary, careful patient monitoring is essential.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available published data and decades of clinical use with lidocaine in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Local anesthetics may cause varying degrees of toxicity to the mother and fetus and adverse reactions include alterations of the central nervous system, peripheral vascular tone and cardiac function (see *Clinical Considerations*).

In published reproduction studies, performed in rats, lower fetal body weights were reported when dosed up to 9.7 times the maximum recommended daily dose during the period of organogenesis and developmental delays in neonates when dosed 0.1 times the maximum recommended daily dose on Gestation Day 11 (see *Data*).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Maternal Adverse Reactions

During treatment of systemic toxicity, which may appear as maternal hypotension or fetal bradycardia, the parturient should be maintained in the left lateral decubitus position if possible or manual displacement of the uterus off the great vessels be accomplished. Elevating the patient's legs will also help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable.

Data

Animal Data

Reproduction studies with lidocaine have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine.

In a published study, lidocaine administered to pregnant rats by continuous subcutaneous infusion during the period of organogenesis at 100, 250, and 500 mg/kg/day, did not produce any structural abnormalities, but did result in lower fetal weights at 500 mg/kg/day dose (approximately 9.7 times the maximum daily dose [MDD] of 500 mg on a mg/m2 basis) in the absence of maternal toxicity.

In a published study, lidocaine containing 1:100,000 epinephrine at a dose of 6 mg/kg (approximately 0.1 times the MDD for lidocaine on a mg/m2 basis) injected into the masseter muscle of the jaw or into the gum of the lower jaw of pregnant Long-Evans hooded rats on Gestation Day 11 resulted in developmental delays in the neonates. Developmental delays were observed for negative geotaxis, static righting reflex, visual discrimination response, sensitivity and response to thermal and electrical shock stimuli, and water maze acquisition. The developmental delays of the neonatal animals were transient, with responses becoming comparable to untreated animals later in life. The clinical relevance of these animal data is uncertain.

8.2 Lactation

Risk Summary

Published data report the presence of lidocaine and its metabolites in human milk in low amounts, along with poor oral bioavailability. There are no data on the effect of lidocaine on the breastfed infant or the effect on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for FLAVALTA and any potential adverse effects on the breastfed child from FLAVALTA or from the underlying maternal condition.

8.4 Pediatric Use

Dosages in pediatric population should be reduced, commensurate with body weight and physical condition [see *Dosage and Administration* (2.2)].

8.5 Geriatric Use

Elderly patients should be given reduced doses commensurate with their age and physical condition.

8.6 Hepatic Impairment

Amide-type local anesthetics such as lidocaine are metabolized by the liver. Patients with severe hepatic impairment, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations and potentially local anesthetic systemic toxicity. Therefore, consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment treated with FLAVALTA, especially with repeat doses [see *Warnings and Precautions* (5.5)].

10 OVERDOSAGE

10.1 Clinical Presentation

Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended intravascular injection of local anesthetic solution [see *Warnings and Precautions* (5), *Adverse Reactions* (6)].

If not treated immediately, convulsions with simultaneous hypoxia, hypercarbia, and acidosis plus myocardial depression from the direct effects of lidocaine may result in cardiac arrhythmias, bradycardia, asystole, ventricular fibrillation, or cardiac arrest. Respiratory abnormalities, including apnea, may occur. If cardiac arrest should occur, successful outcome may require prolonged resuscitative efforts.


10.2 Management of local anesthetic emergencies

The first step in the management of systemic toxic reactions consists of immediate attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask. Endotracheal intubation, using drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask if difficulty is encountered in the maintenance of a patent airway, or if prolonged ventilatory support (assisted or controlled) is indicated.

A bolus intravenous dose of a benzodiazepine will counteract central nervous system stimulation related to FLAVALTA. Immediately after the institution of ventilatory measures, evaluate the adequacy of circulation. Supportive treatment of circulatory depression may require Advanced Cardiac Life Support measures.


11 DESCRIPTION

FLAVALTA is a clear and colorless sterile isotonic solution containing a local anesthetic agent, Lidocaine Hydrochloride, and a vasoconstrictor, Epinephrine (as bitartrate) and is administered parenterally by injection. FLAVALTA is available in single dose cartridges of 1.7 mL [see *Indications and Usage (1)*]. FLAVALTA solution contains lidocaine hydrochloride which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-monohydrochloride, and has the following structural formula:



M.W. 288.8

Epinephrine is (-)-3,4-Dihydroxy- α -{[(Methylamino) methyl] benzyl alcohol and has the following structural formula:



M.W. 183.21

Each mL of FLAVALTA contains 20 mg lidocaine hydrochloride (equivalent to 17.31 mg lidocaine), and 0.01 mg epinephrine (equivalent to 0.018 mg epinephrine bitartrate) with 0.25 mg edetate disodium, 1.2 mg potassium metabisulfite, 6.5 mg sodium chloride and 1 mL water for injections q.s. ad. The flavoring agents are 20.0 mg L-serine and 0.9 mg sodium saccharin. The pH of the FLAVALTA solution is adjusted with sodium hydroxide to 3.3 – 5.5.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses, thereby effecting local anesthetic action.

Epinephrine is a vasoconstrictor added to lidocaine to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration

12.2 Pharmacodynamics

Onset and duration of anesthesia

When used for infiltration anesthesia in dental patients, the time of onset averages less than two minutes for FLAVALTA. FLAVALTA (lidocaine HCl 2% solution with a 1:100,000 epinephrine concentration) provides an average pulp anesthesia of at least 60 minutes with an average duration of soft tissue anesthesia of approximately 2½ hours.

When used for nerve blocks in dental patients, the time of onset for FLAVALTA averages 2 - 4 minutes. FLAVALTA (lidocaine HCl 2% solution with a 1:100,000 epinephrine concentration) provides pulp anesthesia averaging at least 90 minutes with an average duration of soft tissue anesthesia of 3 to 3½ hours.

Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0 µg free base per mL.

Hemodynamics

Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system and/or the beta-adrenergic receptor stimulating action of epinephrine when present.

12.3 Pharmacokinetics

Absorption

Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration.

Distribution

The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentration of 1 to 4 µg of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.

Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion.

Elimination

The elimination half-life of lidocaine hydrochloride following an intravenous bolus injection is typically 1.5 to 2 hours.

Metabolism

Lidocaine is metabolized rapidly by the liver. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine.

Excretion

Lidocaine metabolites and the unchanged drug are excreted by the kidneys. Approximately 90% of lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline.

Specific Populations

Patients with Hepatic Impairment

Because of the rapid rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction.

Patients with Renal Impairment

Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of lidocaine and epinephrine.

Mutagenesis

The mutagenic potential of lidocaine and epinephrine has not been determined.

Impairment of Fertility

In a published study, female Sprague-Dawley rats were treated subcutaneously with lidocaine via osmotic pumps starting two weeks prior to mating, and reproductive effects were assessed. Rat doses up to the high dose of 500 mg/kg/day (approximately 9.7 times the maximum daily dose of 500 mg on a mg/m2 basis) showed no effects on copulatory rate, pregnancy rate, or the numbers of corpora lutea or implantations.

16 HOW SUPPLIED/STORAGE AND HANDLING

FLAVALTA (lidocaine hydrochloride and epinephrine injection) contains lidocaine hydrochloride 2% (34 mg/1.7 mL) (20 mg/mL) and epinephrine 1:100,000 (0.017 mg/1.7 mL) (0.01 mg/mL) supplied in cardboard boxes containing five blisters of ten 1.7 mL single-dose cartridges. The solution is clear and colorless (NDC is 0362-1200-50).

Store at 20° - 25°C (68° - 77°F). Excursions between 15° and 30°C (59° and 86°F) are allowed. Protect from light. Do not freeze.

BOXES: For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the end flap. Do not use if color is pinkish or darker than slightly yellow or if it contains a precipitate.

Sterilization Storage and Technical Procedures

- Cartridges should not be autoclaved, because the closures employed cannot withstand autoclaving temperatures and pressures.
- If chemical disinfection of anesthetic cartridges is desired, either isopropyl alcohol (91%) or 70% ethyl alcohol is recommended. Many commercially available brands of rubbing alcohol, as well as solution of ethyl alcohol not of U.S.P grade, contain denaturants that are injurious to rubber and, therefore, are not to be used. It is recommended that chemical disinfection be accomplished just prior to use by wiping the cartridge cap thoroughly with a pledge of cotton that has been moistened with recommended alcohol.
- Certain metallic ions (mercury, zinc, copper, etc.) have been related to swelling and edema after local anesthesia in dentistry. Therefore, chemical disinfectants containing or releasing these ions are not recommended. Antirust tablets usually contain sodium nitrite or some similar agents that may be capable of releasing metal ions. Because of this, aluminium sealed cartridges should not be kept in such solution.
- Quaternary ammonium salts, such as benzalkonium chloride, are electrolytically incompatible with aluminium. Cartridges of FLAVALTA are sealed with aluminium caps and therefore should not be immersed in any solution containing these salts.
- To avoid leakage of solution during injection, be sure to penetrate the center of the rubber diaphragm when loading the syringe. An off-center penetration produces an oval shaped puncture that allows leakage around the needle. Other causes of leakage and breakage include badly worn syringes, aspirating syringes with bent harpoons, the use of syringes not designed to take 1.7 mL cartridges, and inadvertent freezing.
- Cracking of glass cartridges is most often the result of an attempt to use a cartridge with an extruded plunger. An extruded plunger loses its lubrication and can be forced back into the cartridge only with difficulty. Cartridges with extruded plungers should be discarded.
- Store at 20° - 25°C (68° - 77°F). Excursions between 15° and 30°C (59° and 86°F) are allowed.

17 PATIENT COUNSELING INFORMATION

Allergic-Type Reactions

Assess if the patient has had allergic-type reactions to amide-type local anesthetics or to other formulation ingredients, such as the sulfites in epinephrine-containing solutions [see *Contraindications (4)*, *Warnings and Precautions (5.4)*, *Adverse Reactions (6)*].

Instructions after FLAVALTA injection

The patient should be informed of the possibility of temporary loss of sensation and muscle function following infiltration or nerve block injections. Advise patients not to chew solid foods or to test the anesthetized area by biting or probing until anesthesia has worn off (approximately 3 to 3.5 hours) to avoid inadvertent trauma to the lips, tongue, cheek mucosae or soft palate when these structures are anesthetized.

Methemoglobinemia

Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue [see *Warnings and Precautions (5.2)*].

Manufactured for SEPTODONT, Inc., 205 Granite Run Dr., Suite 150, Lancaster, PA, USA 17601

by Novocel Pharmaceutical of Canada, Inc., 25 Wolseley Court, Cambridge, Ontario, Canada N1R 6X3

Rev. 03/2026 (20060-1)



NEW!

Flavalta™

LIDOCAINE HYDROCHLORIDE 2%
AND EPINEPHRINE 1:100,000

THE FIRST AND ONLY LIDOCAINE
WITH FLAVORING AGENTS



septodontusa.com

From the manufacturer of Septocaine®

R0526